Court Rules YUTREPIA Infringes Two UTHR Patent Claims; Remedies Due in a Week
LQDA has more than doubled off its 52-week low of $21.35 on elevated volume (1.9× avg).
Summary
On September 30, 2026, a Delaware court ruled that claims 1 and 14 of United Therapeutics' '327 patent are valid and infringed by Liquidia's YUTREPIA, while invalidating other asserted claims. The court ruled on two of the six claims asserted against Liquidia, and claims 1 and 14 cover treating PH-ILD patients with inhaled treprostinil, including dry powder. Liquidia intends to submit a supplement to Yutrepia's New Drug Application to FDA to remove PH-ILD from the label. Remedy proposals are due within a week, with potential outcomes ranging from PH-ILD label removal to broader market restrictions or an injunction; United Therapeutics asked the court for injunctive relief in post-trial briefs. Liquidia cannot reasonably estimate the range of potential outcomes or financial exposure. Liquidia plans to appeal. This follows the earlier 25% share drop on the motion-to-strike denial, but adds concrete claim findings and a near-term remedy timeline. The ruling directly threatens YUTREPIA's market presence, which drove $170.4M in Q2 sales. Watch for the remedy proposal and any injunction decision in the coming week.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — On September 30, 2026, the court ruled that claims 1 and 14 of the '327 patent are valid and infringed by Liquidia, while the remaining asserted claims were found invalid.
- Claim Findings — The court ruled on two of the six claims asserted against Liquidia. Claims 1 and 14 cover treating PH-ILD patients with inhaled treprostinil, including dry powder.
- Financial Exposure — Liquidia cannot reasonably estimate the range of potential outcomes or financial exposure.
- Injunctive Relief — United Therapeutics asked the court for injunctive relief in post-trial briefs.
All 4 details
- The court ruled on two of the six claims asserted against Liquidia.
- Claims 1 and 14 cover treating PH-ILD patients with inhaled treprostinil, including dry powder.
- Liquidia cannot reasonably estimate the range of potential outcomes or financial exposure.
- United Therapeutics asked the court for injunctive relief in post-trial briefs.
At the time of this announcement, LQDA was trading at $53.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $21.35 to $93.61. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.